ICOS and inflammation: The loss of ICOS on murine ILC2s or blocking of the ICOS:ICOSL interactions in human ILC2s reduced airway hyperreactivity and lung inflammation by interfering with cytokine-dependent STAT5 activation and resulting impairment in IL-13 release [53,54].